Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy

Autor: Cortellini, A., Ricciuti, B., Facchinetti, F., Alessi, J.V.M., Venkatraman, D., Dall'Olio, F.G., Cravero, P., Vaz, V.R., Ottaviani, D., Majem, M., Piedra, A., Sullivan, I., Lee, K.A., Lamberti, G., Hussain, N., Clark, J., Bolina, A., Barba, A., Benitez, J.C., Gorría, T., Mezquita, L., Hoton, D., Aboubakar Nana, F., Besse, B., Awad, M.M., Pinato, D.J.

Publikováno v: In Annals of Oncology November 2021 32(11):1391-1399

The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.

Autor: Viñolas N; Department of Medical Oncology, Barcelona Clinic Hospital, Translational Genomics and Targeted Therapies in Solid Tumours, IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain. nvinolas@clinic.cat., Mezquita L; Department of Medical Oncology, Barcelona Clinic Hospital, Translational Genomics and Targeted Therapies in Solid Tumours, IDIBAPS, C. de Villarroel, 170, 08036, Barcelona, Spain., Corral J; Department of Medical Oncology, Jerez de la Frontera University Hospital, Cádiz, Spain., Cobo M; Department of Medical Oncology, Virgen de la Victoria University Hospital, Málaga, Spain., Gil-Moncayo F; Department of Psycho-Oncology, Catalan Institute of Oncology-Hospitalet, Barcelona, Spain., Paz-Ares L; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain., Remon J; Department of Medical Oncology, HM Nou Delfos Hospital, Barcelona, Spain., Rodríguez M; Department of Thoracic Surgery, Clínica Universidad de Navarra, Madrid, Spain., Ruano-Raviña A; Department of Medicine and Public Health, Santiago de Compostela University, Santiago de Compostela, Spain., Conde E; Pathology Department, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (Imas12), CIBERONC, Madrid, Spain., Majem M; Department of Medical Oncology, Santa Creu y Sant Pau University Hospital, Barcelona, Spain., Garrido P; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain., Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Isla D; Department of Medical Oncology, Lozano Blesa University Clinical Hospital, Saragossa, Spain., de Castro J; Department of Medical Oncology, La Paz University Hospital, Madrid, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Feb; Vol. 26 (2), pp. 352-362. Date of Electronic Publication: 2023 Jul 25.

Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials.

Autor: Zoghbi M; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Patel BA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Roulleaux Dugage M; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, 94805 Villejuif, France., Mezquita L; Department of Medical Oncology, IDIBAPS, Hospital Clínic, 08036 Barcelona, Spain.; Department of Medicine, University of Barcelona, 08036 Barcelona, Spain., Bahleda R; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, 94805 Villejuif, France., Dufresne A; Département d'Oncologie Médicale, Centre Léon Bérard, 69008 Lyon, France., Brahmi M; Département d'Oncologie Médicale, Centre Léon Bérard, 69008 Lyon, France., Ray-Coquard I; Département d'Oncologie Médicale, Centre Léon Bérard, 69008 Lyon, France., Pautier P; Département de Médecine Oncologique, Gustave Roussy, 94805 Villejuif, France., Blay JY; Département d'Oncologie Médicale, Centre Léon Bérard, 69008 Lyon, France., Le Cesne A; International Department, Gustave Roussy, 94805 Villejuif, France., Massard C; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, 94805 Villejuif, France., Besse B; Département de Médecine Oncologique, Gustave Roussy, 94805 Villejuif, France., Auclin E; Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France., Nassif Haddad EF; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Publikováno v: Cancers [Cancers (Basel)] 2024 Dec 03; Vol. 16 (23). Date of Electronic Publication: 2024 Dec 03.

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Autor: Skoulidis F; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. fskoulidis@mdanderson.org., Araujo HA; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Do MT; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Qian Y; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sun X; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cobo AG; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le JT; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montesion M; Foundation Medicine, Cambridge, MA, USA., Palmer R; Pionyr Immunotherapeutics, South San Francisco, CA, USA., Jahchan N; Pionyr Immunotherapeutics, South San Francisco, CA, USA., Juan JM; D2G Oncology, Mountain View, CA, USA., Min C; Tango Therapeutics, Boston, MA, USA., Yu Y; Tango Therapeutics, Boston, MA, USA., Pan X; Tango Therapeutics, Boston, MA, USA., Arbour KC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vokes N; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schmidt ST; Department of Genomic Medicine and the Institute for Data Science in Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Molkentine D; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Owen DH; Division of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA., Memmott R; Division of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA., Patil PD; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Marmarelis ME; Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Murray JC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Hellyer JA; Department of Genetics, Stanford University, Stanford, CA, USA., Gainor JF; Massachussetts General Hospital, Boston, MA, USA., Dimou A; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Bestvina CM; Department of Medicine, University of Chicago, Chicago, IL, USA., Shu CA; Columbia University, New York, NY, USA., Riess JW; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Blakely CM; University of California San Francisco, San Francisco, CA, USA., Pecot CV; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Mezquita L; Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain., Tabbó F; Ospedale Michele e Pietro Ferrero, Cuneo, Italy., Scheffler M; Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany., Digumarthy S; Department of Radiology, Massachussetts General Hospital, Boston, MA, USA., Mooradian MJ; Massachussetts General Hospital, Boston, MA, USA., Sacher AG; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Lau SCM; Department of Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA., Saltos AN; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Rotow J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Johnson RP; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Liu C; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stewart T; Division of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA., Goldberg SB; Yale School of Medicine, New Haven, CT, USA., Killam J; North Shore University Hospital, Manhasset, NY, USA., Walther Z; Department of Pathology, Yale School of Medicine, New Haven, CT, USA., Schalper K; Department of Pathology, Yale School of Medicine, New Haven, CT, USA., Davies KD; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Woodcock MG; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Anagnostou V; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Marrone KA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Forde PM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Venkatraman D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cummings AL; David Geffen School of Medicine at the University of California, Los Angeles, CA, USA., Goldman JW; David Geffen School of Medicine at the University of California, Los Angeles, CA, USA., Shaish H; Columbia University, New York, NY, USA., Kier M; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Katz S; Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Aggarwal C; Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Ni Y; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Azok JT; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Segal J; Department of Pathology, University of Chicago, Chicago, USA., Ritterhouse L; Foundation Medicine, Cambridge, MA, USA., Neal JW; Department of Genetics, Stanford University, Stanford, CA, USA., Lacroix L; Institut Gustave Roussy, Villejuif, France., Elamin YY; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Negrao MV; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le X; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lam VK; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Lewis WE; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kemp HN; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carter B; Department of Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roth JA; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Swisher S; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee R; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhou T; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Poteete A; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kong Y; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takehara T; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Paula AG; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Parra Cuentas ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Behrens C; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Blumenschein GR; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gay C; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Byers LA; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gibbons DL; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsao A; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee JJ; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bivona TG; University of California San Francisco, San Francisco, CA, USA., Camidge DR; University of Colorado Cancer Center, Denver, CO, USA., Gray JE; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Lieghl N; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Levy B; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Brahmer JR; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Garassino MC; Department of Medicine, University of Chicago, Chicago, IL, USA., Gandara DR; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Garon EB; David Geffen School of Medicine at the University of California, Los Angeles, CA, USA., Rizvi NA; Synthekine, Menlo Park, CA, USA., Scagliotti GV; University of Turin, Orbassano, Italy., Wolf J; Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany., Planchard D; Institut Gustave Roussy, Villejuif, France., Besse B; Institut Gustave Roussy, Villejuif, France., Herbst RS; Yale School of Medicine, New Haven, CT, USA., Wakelee HA; Department of Genetics, Stanford University, Stanford, CA, USA., Pennell NA; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Shaw AT; Novartis Institute for Biomedical Research, Cambridge, MA, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Carbone DP; Division of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA., Hellmann MD; AstraZeneca, Gaithersburg, MD, USA., Rudin CM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Albacker L; Foundation Medicine, Cambridge, MA, USA., Mann H; AstraZeneca, Cambridge, UK., Zhu Z; AstraZeneca, Cambridge, UK., Lai Z; AstraZeneca, Cambridge, UK., Stewart R; AstraZeneca, Cambridge, UK., Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland., Johnson ML; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA., Wong KK; Division of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA., Huang A; Tango Therapeutics, Boston, MA, USA., Winslow MM; D2G Oncology, Mountain View, CA, USA.; Department of Genetics, Stanford University, Stanford, CA, USA., Rosen MJ; D2G Oncology, Mountain View, CA, USA., Winters IP; D2G Oncology, Mountain View, CA, USA., Papadimitrakopoulou VA; Pfizer, New York, NY, USA., Cascone T; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jewsbury P; AstraZeneca, Cambridge, UK., Heymach JV; Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jheymach@mdanderson.org.

Publikováno v: Nature [Nature] 2024 Nov; Vol. 635 (8038), pp. 462-471. Date of Electronic Publication: 2024 Oct 09.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Autor: Mazieres, J. ^*, Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.

Publikováno v: In Annals of Oncology August 2019 30(8):1321-1328